Novo Nordisk Shares rose 8% on Monday his and hers Said it would withdraw generic weight-loss drugs from the market.

Wegovy maker Novo Nordisk and the U.S. Food and Drug Administration threaten legal action It competes with Hims & Hers, which announced over the weekend that it would not sell the pill.

“Since launching semaglutide on our platform, we have had constructive conversations with stakeholders across the industry,” Hims & Hers release Saturday on social media.

“As a result, we have decided to cease offering this treatment. We remain committed to serving the millions of Americans who rely on us for safe, affordable and personalized care.”

This is a breaking news story. Please refresh for updates.